EGFR and non-small cell lung carcinoma: The prevalence of EGFR mutations among Vietnamese NSCLC patients was markedly lower than East Asia cohort (37.7% versus 73.4%, p < 0.00001, Table 3) but significantly higher than MSK-IMPACT cohorts (37.7% versus 29.1%, p < 0.05, Table 3), confirming previous reports that EGFR mutations are more prevalent in Asian patients than in Caucasian patients50.